Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
Goldman Sachs is unimpressed by Cochlear management's "bullish" commentary
Growth Shares
Should you buy CSL and these ASX healthcare shares?
Share Gainers
ALL ORDINARIES finishes lower Friday: 8 shares you missed
Share Market News
Why Healius shares are climbing on its profit report
Share Gainers
Why Baby Bunting, Cochlear, Healius, & Star Entertainment raced higher today
Share Market News
ASX 200 lunch time report: ANZ & Telstra lower, Cochlear higher
Share Gainers
Cochlear share price jumps on higher dividend and outlook
Share Market News
5 things to watch on the ASX 200 on Friday
⏸️ Investing
Is the Cochlear share price a buy?
Share Market News
Cochlear shares tumble and Goldman Sachs's gun analysts are sitting on the fence
Share Market News
Top broker downgrades Cochlear shares
Share Market News
Next week is a huge one for the ASX 200 as earnings season ramps up
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
